Dr. Rana McKay

But that's sort of the spectrum, I think, across the way, the intensity and the potency and the duration is really largely been driven by the risk, the patient risk factors.

But that's sort of the spectrum, I think, across the way, the intensity and the potency and the duration is really largely been driven by the risk, the patient risk factors.

But that's sort of the spectrum, I think, across the way, the intensity and the potency and the duration is really largely been driven by the risk, the patient risk factors.

For just ADT alone without an ARSI, just straight up by itself?

For just ADT alone without an ARSI, just straight up by itself?

For just ADT alone without an ARSI, just straight up by itself?

Yeah, you know, I think that's a very good question. You know, I think at the end of the day, it depends on the patient's symptoms, their goals of care, their quality of life. I think if there's somebody that is maybe has high risk localized disease, the treatment's going to be resultant in a lot of morbidity from surgery or morbidity from radiation.

Yeah, you know, I think that's a very good question. You know, I think at the end of the day, it depends on the patient's symptoms, their goals of care, their quality of life. I think if there's somebody that is maybe has high risk localized disease, the treatment's going to be resultant in a lot of morbidity from surgery or morbidity from radiation.

Yeah, you know, I think that's a very good question. You know, I think at the end of the day, it depends on the patient's symptoms, their goals of care, their quality of life. I think if there's somebody that is maybe has high risk localized disease, the treatment's going to be resultant in a lot of morbidity from surgery or morbidity from radiation.

but they're high risk enough that you really don't want them to develop metastases. And there could be the potential that they would develop metastases in their lifetime. You can certainly think about doing ADT in that context, but I think it's very personalized depending on the patient's comorbidities and also what their goals of care are.

but they're high risk enough that you really don't want them to develop metastases. And there could be the potential that they would develop metastases in their lifetime. You can certainly think about doing ADT in that context, but I think it's very personalized depending on the patient's comorbidities and also what their goals of care are.

but they're high risk enough that you really don't want them to develop metastases. And there could be the potential that they would develop metastases in their lifetime. You can certainly think about doing ADT in that context, but I think it's very personalized depending on the patient's comorbidities and also what their goals of care are.

Yeah, no, very good question. You know, I think that, you know, a lot of times we're talking about one, what's the intent of treatment, but we're going through a lot of the side effects, you know, a lot of times, the bulk of the clinic visit is spent around, well, this is all the risks that are associated with ADT.

Yeah, no, very good question. You know, I think that, you know, a lot of times we're talking about one, what's the intent of treatment, but we're going through a lot of the side effects, you know, a lot of times, the bulk of the clinic visit is spent around, well, this is all the risks that are associated with ADT.

Yeah, no, very good question. You know, I think that, you know, a lot of times we're talking about one, what's the intent of treatment, but we're going through a lot of the side effects, you know, a lot of times, the bulk of the clinic visit is spent around, well, this is all the risks that are associated with ADT.

And these are all the things we need to guard against when you go on hormonal therapy. So I think it's an overview of sort of the risk and the toxicity. But I think with regards to the different agents, there's a ton of different agents that are out there. And

And these are all the things we need to guard against when you go on hormonal therapy. So I think it's an overview of sort of the risk and the toxicity. But I think with regards to the different agents, there's a ton of different agents that are out there. And

And these are all the things we need to guard against when you go on hormonal therapy. So I think it's an overview of sort of the risk and the toxicity. But I think with regards to the different agents, there's a ton of different agents that are out there. And

There are certain things that I think we do in clinical practice because they're just very practical and feasible to orchestrate in the clinic. But, you know, technically at the end of the day, there's like Degarelix that can be given as a one month subcutaneous injection. There's, you know, Luprolide or Trelstar that are given as

There are certain things that I think we do in clinical practice because they're just very practical and feasible to orchestrate in the clinic. But, you know, technically at the end of the day, there's like Degarelix that can be given as a one month subcutaneous injection. There's, you know, Luprolide or Trelstar that are given as